Ingmar Gorman

Specialized psychedelic clinical trial services provider focused on therapist and facilitator training, protocol/manual support, adherence frameworks, and sponsor-facing trial preparation.

Care-delivery platform for ketamine-assisted psychotherapy enabling licensed therapists to deliver KAP through a coordinated technology and prescriber network model.

The Center for Psychedelic Medicine at NYU Langone Health is directed by Dr. Michael Bogenschutz and performs health-focused research across the translational spectrum, from basic science to large-phase clinical trials. The center has three transdisciplinary areas of focus: psychiatry, medicine, and preclinical research. Currently, the team is actively investigating clinical applications for various psychedelic compounds, leading robust studies on psilocybin-assisted therapy for alcohol use disorder, major depression, and advanced cancer-related psychiatric distress.

MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.

The International Alliance of MDMA Practitioners, also known as the MDMA Alliance, is a nonprofit professional organization for practitioners who offer MDMA-assisted therapy in legal settings. Its public materials describe a global network of experienced clinicians and researchers who provide community, resources, training, continuing education, and referral connections for members. The organization says it serves licensed mental health and healthcare practitioners, including international members, who have MDMA-assisted therapy or related psychedelic therapy experience. The MDMA Alliance presents itself as a field-building group focused on advancing MDMA-assisted therapy through education, advocacy, community, and best-practice development. It says it advocates for the appropriate use of MDMA-assisted therapy as the field evolves, and that it will develop clinical and ethical standards for the profession. Public-facing materials also describe member activities such as monthly meetings, in-person retreats, an online forum, a resource hub, and a referral list of therapists and supervisors.